Lumify is a drug owned by Bausch And Lomb Inc. It is protected by 4 US drug patents filed from 2018 to 2023 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 14, 2030. Details of Lumify's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US9259425 | Compositions and methods for eye whitening |
Jul, 2030
(5 years from now) | Active |
| US8293742 | Preferential vasoconstriction compositions and methods of use |
Jul, 2030
(5 years from now) | Active |
| US11833245 | Vasoconstriction compositions and methods of use |
Jul, 2029
(4 years from now) | Active |
| US11596600 | Vasoconstriction compositions and methods of use |
Jul, 2029
(4 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Lumify's patents.
Latest Legal Activities on Lumify's Patents
Given below is the list of recent legal activities going on the following patents of Lumify.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Maintenance Fee Reminder Mailed Critical | 10 Jun, 2024 | US8293742 |
| Petition Requesting Trial | 15 Mar, 2024 | US11596600 |
| Petition Requesting Trial | 15 Feb, 2024 | US11833245 |
| Recordation of Patent Grant Mailed Critical | 05 Dec, 2023 | US11833245 |
| Patent Issue Date Used in PTA Calculation Critical | 05 Dec, 2023 | US11833245 |
| Email Notification Critical | 05 Dec, 2023 | US11833245 |
| Patent eGrant Notification | 05 Dec, 2023 | US11833245 |
| Recordation of Patent eGrant | 05 Dec, 2023 | US11833245 |
| Mail Patent eGrant Notification | 05 Dec, 2023 | US11833245 |
| Email Notification Critical | 16 Nov, 2023 | US11833245 |
While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Lumify and ongoing litigations to help you estimate the early arrival of Lumify generic.
Lumify's Litigations
Lumify been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Nov 04, 2021, against patent number US9259425. The petitioner Slayback Pharma LLC, challenged the validity of this patent, with Eye Therapies, LLC as the respondent. Click below to track the latest information on how companies are challenging Lumify's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US11596600 | February, 2024 | Pending | Eye Therapies, LLC et al. | Dr. Reddy's Laboratories S.A. et al. |
| US11833245 | January, 2024 |
Trial Instituted
(13 Aug, 2024) | Eye Therapies, LLC et al. | Dr. Reddy's Laboratories S.A. et al. |
| US8293742 | November, 2021 |
Final Written Decision - Appealed
(15 May, 2023) | Eye Therapies, LLC et al. | Slayback Pharma LLC et al. |
| US9259425 | November, 2021 |
Terminated-Settled
(05 Oct, 2022) | Eye Therapies, LLC | Slayback Pharma LLC |
FDA has granted some exclusivities to Lumify. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Lumify, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Lumify.
Exclusivity Information
Lumify holds 1 exclusivities. All of its exclusivities have expired in 2020. Details of Lumify's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 22, 2020 |
US patents provide insights into the exclusivity only within the United States, but Lumify is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Lumify's family patents as well as insights into ongoing legal events on those patents.
Lumify's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Lumify's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jul 14, 2030 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Lumify Generic API suppliers:
Brimonidine Tartrate is the generic name for the brand Lumify. 13 different companies have already filed for the generic of Lumify, with Sandoz having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Lumify's generic
How can I launch a generic of Lumify before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Lumify's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Lumify's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Lumify -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 0.00025 | 12 Jul, 2021 | 1 | 14 Jul, 2030 |
Alternative Brands for Lumify
Lumify which is used for relieving redness in the eyes caused by minor eye irritations., has several other brand drugs using the same active ingredient (Brimonidine Tartrate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | ||
|---|---|---|---|
| Abbvie |
| ||
| Alcon Labs Inc |
| ||
| Bausch And Lomb Inc |
| ||
| Galderma Labs Lp |
| ||
| Sandoz |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Brimonidine Tartrate, Lumify's active ingredient. Check the complete list of approved generic manufacturers for Lumify
About Lumify
Lumify is a drug owned by Bausch And Lomb Inc. It is used for relieving redness in the eyes caused by minor eye irritations. Lumify uses Brimonidine Tartrate as an active ingredient. Lumify was launched by Bausch And Lomb Inc in 2017.
Approval Date:
Lumify was approved by FDA for market use on 22 December, 2017.
Active Ingredient:
Lumify uses Brimonidine Tartrate as the active ingredient. Check out other Drugs and Companies using Brimonidine Tartrate ingredient
Treatment:
Lumify is used for relieving redness in the eyes caused by minor eye irritations.
Dosage:
Lumify is available in solution/drops form for ophthalmic use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.025% | SOLUTION/DROPS | Over the counter | OPHTHALMIC |